GlassScriptPhysician profile
Mindy A Howard
NPI 1447663257
$6,768.06
in general payments reported to CMS, 2019-2025
31 companies · $1,457 in 2025
The $1,457 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $86.10 · 2022: $1,210 · 2023: $1,242 · 2024: $2,773 · 2025: $1,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,361 · Travel and Lodging: $917 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,361.04 |
| Travel and Lodging | $917.23 |
| Education | $193.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,373.54 | 2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $771.26 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $750.56 | 2022-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $600.85 | 2022-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $521.59 | 2022-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $447.86 | 2022-2025 | |
| Mylan Specialty L.P. | $440.90 | 2022-2024 | Yupelri |
| Insmed, INC. | $223.83 | 2022-2025 | Arikayce, Brinsupri |
| Pfizer INC. | $211.73 | 2023-2025 | |
| Lilly USA, LLC | $154.93 | 2024-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $140.94 | 2021-2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $134.33 | 2022-2025 | Cuvitru, Hyqvia |
| Janssen Pharmaceuticals, INC | $116.20 | 2021-2024 | Xarelto |
| United Therapeutics Corporation | $107.76 | 2022-2025 | Tyvaso, Tyvaso |
| Viatris Specialty LLC | $106.37 | 2025 | Yupelri |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $83.69 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Sanofi-Aventis U.S. LLC | $76.99 | 2022 | |
| Paratek Pharmaceuticals, INC. | $72.91 | 2022-2025 | Nuzyra |
| Amgen INC. | $63.46 | 2022-2024 | Tezspire |
| Grifols USA, LLC | $63.24 | 2022-2024 | Prolastin-C Liquid |
| Verona Pharma, INC. | $62.85 | 2025 | Ohtuvayre |
| Csl Behring | $57.43 | 2022-2025 | Hizentra |
| Harmony Biosciences LLC | $31.46 | 2023 | Wakix |
| Baxter Healthcare | $30.80 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Actelion Pharmaceuticals US, INC. | $22.54 | 2025 | Uptravi, Opsumit |
| Avadel Cns Pharmaceuticals, LLC | $20.90 | 2025 | Lumryz |
| Philips North America LLC | $17.92 | 2022 | |
| Merck Sharp & Dohme LLC | $16.67 | 2024 | |
| Melinta Therapeutics, LLC | $16.30 | 2023 | Rezzayo, Vabomere |
| Phadia US INC. | $14.48 | 2024 | Immunocap |
| La Jolla Pharmaceutical Company | $13.77 | 2023 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindy Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.